CAR-T Cell Therapy Promising in Multiple Myeloma
Researchers sought to determine whether idecabtagene vicleucel, a CAR-T cell therapy, would be a viable treatment option in heavily pretreated patients with relapsed or refractory multiple myeloma.
Researchers sought to determine whether idecabtagene vicleucel, a CAR-T cell therapy, would be a viable treatment option in heavily pretreated patients with relapsed or refractory multiple myeloma.
Patients who have undergone either autologous or allogeneic hematopoietic stem cell transplantation (HSCT) are at high risk for mortality in the event of a COVID-19 diagnosis.
For patients with iron deficiency anemia, oral iron supplementation use alone is comparable to oral supplementation with vitamin C.
Antibody testing after the early stages of the SARS-CoV-2 pandemic has significantly increased in the proportion of first-time blood donors.
Prescription drug monitoring programs that aim to prevent opioid misuse may be affecting patients with cancer who need pain management.